Bavarian Nordic's PROSTVAC® update & reception June 4, 2012 in Chicago
Thursday, May 24, 2012 at 4:46PM
DDE Editor in Conferences
Bavarian Nordic's PROSTVAC® update & reception will be held in Chicago on Monday, June 4, 2012.
PROSTVAC® is a therapeutic vaccine currently enrolling in a pivotal Phase 3 trial (PROSPECT) of 1,200 patients with asymptomatic or minimally symptomatic castration-resistant prostate cancer that was initiated in November 2011 and is expected to form the basis for approval of the vaccine for this patient population.
Pre-registration for the June 4 event is required and attendance is limited, so please click "
Register Now!" to RSVP today.
Speakers at the event include:
- Dr. James L. Gulley (NCI)
- Dr. Philip W. Kantoff (Dana-Farber)
- Anders Hedegaard (Bavarian Nordic)
- Dr. Reiner Laus (Bavarian Nordic)
Contacts:
Mettes Buhls
Bavarian Nordic
or
Michael Becker
MD Becker Partners
Article originally appeared on Daily Dose Equities - Wall Street Analysis for Biomedical Research (http://dailydoseequities.filmannex.com/).
See website for complete article licensing information.